Table 1.

Epidemiological and clinical features of MPS VII Iberian cohort

Patient	Age at diagnosis/sex	Clinical manifestations	MPS VII treatment
1	8 years/M	Cognitive delay, coarse face, quadriplegia, chest deviations, thoracic kyphosis	None
2	12 months/F	Clubfoot, hip dysplasia, scoliosis, mild aortic thickening, corneal clouding, respiratory issues	Bone marrow and umbilical cord transplants
3	2 years/M	Coarse face, dysostosis, splenomegaly, macrocephaly, psychomotor delay, hip dysplasia, hernias	Vestronidase
4	14 months/M	Hydrops fetalis, hypospadias, skeletal deformities, scoliosis, hepatic hemangiomas	Vestronidase
5	18 months/M	Hydrops fetalis, breathing issues, cognitive and growth delay, severe scoliosis, mild valvular deficiency	Vestronidase
6	2 years/M	Severe trunk issues, lower limb hyperreflexia, hepatomegaly, hernias, cognitive delay	Vestronidase
7	26 months/F	Hydrops fetalis, hip dysplasia, cognitive delay, ENT issues, spinal deformities, osteoporosis	Vestronidase
8	5 months/M	Dysmorphic signs, hepatomegaly, hernias, developmental delay, heart hypertrophy	None
9	3 months/M	Hepatomegaly, psychomotor delay, epilepsy with focal seizures	Vestronidase

F: Female; M: Male; ENT: ear, nose, throat; MPS: Mucopolysaccharidosis